

RESEARCH ARTICLE

Open Access

Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy

José C Álvarez^{1†}, Sonia I Cuervo^{1,2,3†}, Javier R Garzón², Julio C Gómez^{2,3}, Jorge Augusto Díaz^{2,4†}, Edelberto Silva^{2,4,5*†}, Ricardo Sánchez^{1,2,3†} and Jorge A Cortés^{1†}

Abstract

Introduction: Patients with febrile neutropenia (FN) exhibit changes in extracellular fluid that may alter the plasma concentrations of beta-lactams and result in therapeutic failure or toxicity. We evaluated the pharmacokinetics of piperacillin/tazobactam in patients with hematological malignancies and FN after receiving chemotherapy at a primary public cancer center.

Methods: This was an open, nonrandomized, observational, descriptive, and prospective study. Samples from 15 patients with hematological malignancies and FN were evaluated after the administration of chemotherapy. Five blood samples were taken from each patient when the antibiotic level was at steady-state 10, 60, 120, 180, and 350 min after each dose. Antibiotic concentrations were measured using gel diffusion with *Bacillus subtilis*. All study participants provided written informed consent.

Results: We investigated the pharmacokinetics of piperacillin in 14 patients between the ages of 18 years and 59 years and with a mean absolute neutrophil count of 208 cells per mm³ (standard deviation (SD) ± 603.2). The following pharmacokinetic measurements were obtained: maximum concentration, 94.1–1133 mg/L; minimum concentration, 0.47–37.65 mg/L; volume of distribution, 0.08–0.65 L/kg (mean, 0.34 L/kg); drug clearance (CL), 4.42–27.25 L/h (mean, 9.93 L/h); half-life (t_{1/2}), 0.55–2.65 h (mean, 1.38 h); and area under the curve, 115.12–827.16 mg · h/L.

Conclusion: Patients with FN after receiving chemotherapy exhibited significant variations in the pharmacokinetic parameters of piperacillin compared with healthy individuals; specifically, FN patients demonstrated an increase in t_{1/2} and decreased CL.

Keywords: Pharmacokinetics, Piperacillin/tazobactam, Beta-lactam antibiotics, Neutropenia, Fever, Chemotherapy, Hematological malignancies

Background

Variations in the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of hydrophilic antimicrobial agents have been described previously in different pathological conditions (e.g., sepsis, trauma, burns, hypoalbuminemia), in animal models and in clinical trials evaluating

febrile neutropenia (FN). These variations were identified because the extracellular fluid (ECF) levels in these patients were different than in healthy patients. Changes in ECF levels affect the plasma concentrations of antibiotics [1,2].

Beta-lactams are the first-choice antibiotics for the treatment of FN after chemotherapy, and inadequate serum levels of these antibiotics may lead to therapeutic failure. Cefepime, piperacillin/tazobactam, imipenem/cilastatin, and meropenem are beta-lactam antibiotics that exhibit activity against *Pseudomonas aeruginosa*, and these

* Correspondence: esilvag@unal.edu.co

†Equal contributors

²(GREICAH): Grupo de Investigación en Enfermedades Infecciosas en Cáncer y alteraciones hematológicas, Bogotá, Colombia

⁴Departamento de Farmacia, Facultad de Ciencias, Universidad Nacional de Colombia, Bogotá, Colombia

Full list of author information is available at the end of the article

antibiotics are recommended as monotherapy for the empirical treatment of FN after chemotherapy [3].

Little information is available on the kinetic behavior of piperacillin or the piperacillin/tazobactam combination in cancer patients. However, addition of piperacillin or amikacin to moxalactam administration in FN patients has been shown to alter PK parameters compared with healthy individuals [4], and a randomized clinical trial evaluating PK parameters demonstrated a decrease in the volume of distribution (Vd) and drug clearance (CL) and an increase in half-life ($t_{1/2}$) [5].

We investigated the PK parameters of piperacillin in Latin American patients with hematological malignancies and FN after receiving chemotherapy.

Methods

We conducted an open, nonrandomized, observational, descriptive, and prospective study in the Hematology Department of the National Cancer Institute (NCI) in Bogota, Colombia. The Ethics Committees of the National University of Colombia and NCI approved the protocol. All study participants provided written informed consent.

Patients

The inclusion criteria were patients: aged >18 years with a *de novo* diagnosis or recent diagnosis of hematological malignancy; currently undergoing chemotherapy; who had FN after receiving chemotherapy; did not have renal or liver failure; being treated with piperacillin/tazobactam (4.5 g, i.v.) every 6 h in the event of FN. Pregnancy tests were negative for women of reproductive age.

The exclusion criteria were patients: with chronic kidney disease defined as a estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m² [6]; with liver failure defined as Child–Turcotte–Pugh classes B or C [7]; who received combined antimicrobial therapy due to a polymicrobial bloodstream infection.

Definitions

Neutropenia was defined as an absolute neutrophil count <1,000 cells per mm³ or in cases where a count <1,000 cells per mm³ was anticipated 3–5 days after chemotherapy. Neutropenia was also declared in cases of acute leukemia with a neutrophil count with a blast percentage >90%.

Fever was defined as a temperature of 38°C for 1 h or one temperature measurement >38.3°C. FN was secondary to intensive antineoplastic induction, re-induction, or maintenance chemotherapy.

Laboratory tests

Five samples were taken from each of the 15 patients 10, 60, 120, 180, and 350 min after the dose of piperacillin/tazobactam attained a steady state. Piperacillin/tazobactam

was administered as a generic product (Vitalis®) purchased by the institution for use in all patients. The piperacillin content in samples from different batches and patient sera was measured using a biological gel diffusion assay with *Bacillus subtilis* ATCC 6633. The following PK parameters were calculated from the concentration–time plots: maximum concentration (C_{max}), minimum concentration (C_{min}), Vd, CL, $t_{1/2}$, and the area under the curve ($AUC_{0-\infty}$).

Statistical analyses

STATA IC® ver11.1 software was used for analyses. Two-tailed Student's *t*-tests were used to compare independent samples at a significance defined as $p < 0.05$. PK parameters were compared between group of patients with albumin levels >3 g/dL vs. those with <3 g/dL, those who received a piperacillin/tazobactam in bolus dose, and those who received chemotherapy with Hyper-CVAD vs. another chemotherapy regimen (for Hyper-CVAD chemotherapy, course A comprised cyclophosphamide, vincristine, doxorubicin and dexamethasone, and course B consisted of methotrexate and cytarabine).

Results

Originally, the study cohort was 15 patients. However, 1 patient (patient 003) was excluded because the inhibition zone was not clearly visible due to serum hyperviscosity and the white blood cell (WBC) count was 262,400 cells per mm³. The ages of the 14 studied patients ranged from 18 years to 59 years (mean, 31.9 years; standard deviation (SD), 15.4), and 8 of the patients were women. The albumin values recorded were between 2.1 g/dL and 4 g/dL (mean, 3.04 g/dL; SD, 0.56), and the neutrophil count was 0–2,380 cells per mm³ (mean, 208 cells/mm³; SD, 603.2). In 71.4% of patients, the Hyper-CVAD chemotherapy regimen was used alone or in combination with rituximab or imatinib (Table 1).

Concentrations (µg/mL) versus time were plotted for each patient to generate an exponential curve, which was used to calculate PK parameters. Visual inspection revealed one-compartment model behavior of piperacillin/tazobactam. Table 2 presents the PK parameters for each patient.

Statistically significant differences in PK parameters were evaluated by comparing the albumin values (Table 3) in patients with levels <3 g/dL and >3 g/dL and the use of Hyper-CVAD chemotherapy against other regimens.

Discussion

The present study confirmed previous observations of differences in the PK parameters of piperacillin/tazobactam in patients with FN and cancer. Patients with cancer and FN after chemotherapy are prone to cachexia, hypoalbuminemia, and the development of a third space

Table 1 General characteristics of patients

Parameter	Number (%)
Age (years)	
18– 24	7 (50.0)
25 - 31	3 (21.4)
40 - 60	4 (28.6)
Sex	
Female	8 (57.1)
Male	6 (42.9)
Weight (kg)	
40 - 50	5 (35.7)
51 – 60	6 (42.9)
61 - 80	3 (21.4)
Mean ± SD = 56.4 ± 11.2	
Height (cm)	
150 – 160	9 (64.3)
161 – 170	4 (28.6)
171 – 180	1 (7.1)
BMI kg/m²	
17.0 – 22.0	8 (57.2)
22.1 – 27.0	5 (35.7)
27.1 – 32.0	1 (7.1)
Mean ± SD = 21.9 ± 4.0	
Creatinine clearance (mg/mL)	
80 - 110	3 (21.4)
111 - 140	6 (42.9)
141 - 170	5 (35.7)
Albumin g/dL	
2.0 – 2.6	3 (21.4)
2.7 – 3.3	7 (50.0)
3.4 – 4.0	4 (28.6)
Mean ± SD = 3.0 ± 0.6	
Antibiotic given in the previous month?	
Yes	5 (35.7)
No	9 (64.3)
Malignancy	
Lymphoma	2 (14.3)
Lymphoid leukemia	9 (64.3)
Myeloid leukemia	3 (21.4)
Number of neutrophils/mm³	
Range	0–2380
Mean ± SD	208(603.2)
Therapy cycles	
1 – 2	6 (42.9)
3 – 5	3(21.4)
6 - 8	5 (35.7)

Table 1 General characteristics of patients (Continued)

FN-associated chemotherapy	
Hyper-CVAD	10 (71.4)
No Hyper-CVAD	4 (28.6)

BMI, body mass index; FN, febrile neutropenia; GFR, glomerular filtration rate. For Hyper-CVAD chemotherapy, course A comprised cyclophosphamide, vincristine, doxorubicin and dexamethasone, and course B consisted of methotrexate and cytarabine. Mentioned on page 6.

[2]. Furthermore, the high protein content in exudates favors drug binding to proteins, which slows distribution of the drug in the systemic circulation, decreases C_{max} and increases $t_{1/2}$.

The current study, in which piperacillin/tazobactam was administered as a bolus dose every 6 h, confirmed that the C_{min} , elimination rate (K_e), and $t_{1/2}$ parameters of piperacillin/tazobactam were modified in patients whose albumin levels were <3 g/dL. However, patients with an albumin level <3 g/dL would be expected to exhibit a higher free fraction of antibiotic and a higher CL because these two parameters are directly related (renal CL = unbound drug × eGFR) [8]. Indeed, a difference in GFR was observed between subgroups because this rate increased in patients with albumin levels > 3 g/dL. However, other statistically significant differences between these groups were not observed. Organ function can be diminished in patients with lower albumin levels. For example, kidney function may increase tumor progression or decrease functional reserve, and non-renal CL or other non-quantified clinical variables may also be altered.

Table 4 summarizes the values of the means and SD for the calculated PK parameters and other patient characteristics in comparison with the work of Drusano et al. [4], Drusano et al. [5] and Mattoes et al. [9].

Analyses of the piperacillin/tazobactam concentration against time plots revealed a one-compartment model, as described previously in an *in vitro* study by Strayer et al. [10]. The PK parameters of piperacillin alone at 3 g every 6 h were compared with those of 3 g piperacillin every 6 h or 4 g every 8 h in combination with 0.375 g or 0.5 g tazobactam, respectively (Table 3). The PK parameters in our FN patients were related directly to higher Vd and CL values, which explains the similar $t_{1/2}$ value as that observed by Strayer et al. (Table 4) [10].

A one-compartment model of behavior was observed previously when piperacillin/tazobactam was administered as a prolonged infusion to 13 patients who were hospitalized for the treatment of an infectious process [11]. Of these patients, 6 were noncritical and 7 were critical, and they received 4.5 g of piperacillin/tazobactam as a 4-h intravenous infusion every 8 h. These previous results by Shea et al. [11] suggested that the lower $t_{1/2}$ value was due

Table 2 PK parameters for each patient

Patient	C _{max} (µg/mL)	C _{min} (µg/mL)	VD (L/kg)	Ke (h ⁻¹)	CL (L/h)	t _{1/2} (h)	AUC [0-inf]	Dose in mg/kg
1	283.97	13.29	0.26	0.53	7.45	1.31	398.78	54.05
2	200.56	16.87	0.35	0.44	8.70	1.59	419.14	52.63
4	337.21	6.36	0.22	0.69	8.15	1.01	232.15	70.18
5	211.53	18.76	0.35	0.43	8.19	1.60	446.61	46.51
6	153.13	18.74	0.61	0.36	9.30	1.95	311.08	85.11
7	97.37	3.88	0.52	0.57	23.54	1.21	163.28	63.49
8	94.10	2.22	0.65	0.64	27.25	1.08	115.12	58.82
10	465.78	13.64	0.15	0.57	4.93	1.21	607.15	86.96
11	162.34	5.18	0.42	0.53	13.13	1.30	317.32	66.67
12	179.52	37.65	0.45	0.26	5.84	2.65	418.48	60.61
13	318.81	28.34	0.26	0.44	5.48	1.59	667.45	62.50
14	319.55	19.07	0.30	0.50	6.20	1.40	477.15	78.43
15	513.74	4.52	0.10	0.82	6.38	0.85	678.99	86.96
16	1133	0.47	0.08	1.25	4.42	0.55	827.16	66.67
Mean	319.33	13.50	0.34	0.57	9.93	1.38	434.28	67.11
σ(n-1)	266.08	10.71	0.18	0.24	6.95	0.51	205.17	13.01

Mentioned on page 6.

to an increase in CL, despite a similar Vd, for PK parameters (Table 4) [11].

Piperacillin doses between 8 g per day and 18 g per day were administered with tazobactam to four groups of healthy patients. Auclair et al. found that one-compartment model behavior was determined by visual inspection of the logarithmic relationship of plasma and urinary concentrations against time [12]. Piperacillin elimination is accomplished primarily *via* active tubular secretion by the kidney, but elimination is assisted by glomerular filtration and biliary excretion. Saturation of these mechanisms at plasma concentrations of piperacillin/tazobactam is unlikely. A nonlinear elimination, as explained by the Michaelis–Menten equation, would occur in the event of saturation, which would require a different PK analysis (Table 4) [12]. The filtration rate of a drug and the subsequent elimination rate are dependent upon the volume of the glomerular filtrate and free drug concentrations in the plasma (Table 4) [13].

One limitation of this study was the lack of a standardized method for administration of piperacillin/tazobactam by nurses with regard to the reconstitution of the powder

forms of the drugs, solvent volume, or rate of infusion of the diluted antibiotic. This variability underlies representation of the concentration–time plots for antibiotic administration as an infusion in some patients and a bolus in others. Therefore, calculations of PK parameters were undertaken using interpretations of these two modes of drug administration. Mattoes et al. [10] investigated 12 healthy adults who received piperacillin/tazobactam (4.5 g, i.v.) every 6 h and demonstrated that patients with FN exhibited higher values of Vd and lower values of CL. These results may explain the lower values of Ke and higher values of t_{1/2} as compared with healthy individuals. PK parameters were investigated in patients in the intensive care unit (ICU) after administration of a 4-g bolus of piperacillin every 8 h or a 4-g bolus with subsequent continuous 8-g infusion for 24 h. PK parameters in patients who received a bolus administration compared with patients with FN in our study exhibited a similar value of CL and lower value of Vd, which would explain the lower t_{1/2} value compared with ICU patients. Langgartner et al. found that PK parameters often differed in healthy subjects because a previous study found that

Table 3 PK parameters in patients with albumin >3 g/dL and <3 g/dL with statistically significant differences

PK parameter	Albumin <3 g/dL	Albumin >3 g/dL	Student's t-test	P
C _{min} (µg/mL)	8.3	20.4	4.5135	0.0305
Ke (h ⁻¹)	0.7	0.4	-2.4515	0.0486
t _{1/2} (h)	1.1	1.7	-2.5709	0.0245

Mentioned on pages 6 and 8.

Table 4 Summary of PK parameters for piperacillin/tazobactam as compared with other studies

Parameter	Present study	Strayer et al.	Shea et al.	Auclair et al.	Mattoes et al.	Langaartner et al.	Drusano et al. 1985	Drusano et al. 1989
C_{max} (µg/mL)	319.3 ± 266.08	366.7	108.2 ± 31.7	SD	282.2 ± 57.7	231 ± 66	152	SD
C_{min} (µg/mL)	13.5 ± 10.71	SD	27.6 ± 26.3	SD	SD	11.5 ± 14.8	12	SD
VD (L/kg)	0.34 ± 0.18	SD	0.28 ± 0.07	0.12	0.2	34.6*	0.21 ± 0.14	0.13 ± 0.03
Ke (h⁻¹)	0.57 ± 0.24	SD	SD	SD	0.86 ± 0.09	SD	SD	SD
CL (L/h)	9.93 ± 6.45	SD	8.6 ± 3.0	7.8	10.9 ± 2.5	10.23	8.31 ± 3.39	6.1 ± 2.54
t_{1/2} (h)	1.38 ± 0.51	1.3	2.1 ± 1.2	0.9	0.81 ± 0.08	2.4 ± 1.2	1.47 ± 0.95	1.54 ± 0.42
AUC_{[0-∞)} mg·h/L	434.28 ± 205.17	488.9	527.5 ± 216.1	290	380.4 ± 72.6	391 ± 183	635.3 ± 253.2	SD
Weight (kg)	56.4 ± 26.78	<i>In vitro</i>	79.6 ± 13.8	SD	69.8 ± 15.7	60 - 86	69.5	70.2 ± 29.05

*Data shown in L.

Mentioned on pages 7, 8 and 9.

an increase in $t_{1/2}$ and decrease in CL were due to decreased clearance of creatinine (Table 4) [14].

In another study, moxalactam was administered to FN patients and piperacillin or amikacin were included randomly. Drusano et al. measured the following PK parameters for piperacillin: $V_d = 0.21$ (SD = 0.14) L/kg; CL = 8.31 (SD 3.39) L/h/1.73 m²; and $t_{1/2} = 1.47$ (SD = 0.95) h (Table 4) [4]. Furthermore, Drusano et al. conducted a randomized, double-blind clinical trial in which one group received piperacillin and amikacin and the other group received imipenem/cilastatin. PK parameters were measured and decreases were found in V_d (0.13 (SD = 0.03) L/kg) and CL (6.1 (SD = 2.54) L/h/1.73 m²) and an increase in $t_{1/2}$ (1.54 (SD = 0.42) h) noted [5].

Conclusions

We found that piperacillin/tazobactam exhibited a one-compartment model of PK behavior in neutropenic patients. These data are in accordance with those of previous reports.

FN patients after chemotherapy exhibited important variations in PK parameters compared with healthy individuals. FN patients exhibited an increase in $t_{1/2}$ and a decrease in CL.

FN patients should receive piperacillin/tazobactam doses based on weight (75 mg/kg) due to the low weight of these FN patients and the observed variations in plasma concentrations.

Study limitations

One important limitation of this study was the inability to standardize the infusion rate or the amount of piperacillin/tazobactam diluent. This variation caused the values of plasma concentrations of antibiotics to differ from the expected values over time in some patients. This problem necessitated evaluation of the exponential curves from which the PK parameters were calculated with fewer samples than were taken. Serum sample measurements for piperacillin/tazobactam corresponded to those for

different batches from the same drug company, but the piperacillin content in one sample from a different batch was not significantly different (results to be published).

Abbreviations

ECF: Extracellular fluid; FN: Febrile neutropenia; ICU: Intensive care unit; NCI: National cancer institute; PD: Pharmacodynamic; PK: Pharmacokinetic.

Competing interests

The authors declare that they have no competing interest.

Authors' contribution

JCA collaborated on data collection, PK calculations, and drafting of the manuscript. SIC participated in the design and preparation of the manuscript and coordinated the research at the research site. JRG presented the research idea and designed the research protocol. JCG collaborated on the selection and enrolment of patients, project management at the NCI, and data analyses. ES carried out the biological tests and laboratory work. JAD assisted in PK analyses. RS undertook the statistical analyses. JAC assisted in protocol development and data analyses. All of the authors approved the final manuscript and agreed upon its submission to *BMC Pharmacology and Toxicology*.

Acknowledgements

Universidad Nacional de Colombia DIB, School of Science project 202010015111-2010 and Instituto Nacional de Cancerología project 41030310169 by means of the inter-agency teaching assistance agreement with the Universidad Nacional de Colombia in Bogota. VITALIS SACI from the "Research Development Endowment" agreement signed by VITALIS SACI and the Facultad de Ciencias of the Universidad Nacional de Colombia. The group of researchers wants to give special thanks to Dr. María Judith Arias for their Invaluable support in the administration of the project from her work group in the company VITALIS SACI.

Author details

¹Universidad Nacional de Colombia, Facultad de Medicina, Bogotá, Colombia. ²(GREICAH): Grupo de Investigación en Enfermedades Infecciosas en Cáncer y alteraciones hematológicas, Bogotá, Colombia. ³Instituto Nacional de Cancerología, Bogotá, Colombia. ⁴Departamento de Farmacia, Facultad de Ciencias, Universidad Nacional de Colombia, Bogotá, Colombia. ⁵Departamento de Medicina, Facultad de Medicina, Ciudad Universitaria, Carrera 30 No. 45-03, edificio 471, oficina 510, Bogotá A. A. 14490, Colombia.

Received: 29 November 2012 Accepted: 15 November 2013

Published: 28 November 2013

References

- Garzón JR, Cuervo MS, Gómez J, Cortés JA, Farmacocinética y farmacodinamia de antimicrobianos: a propósito de pacientes con

- neutropenia y fiebre: Pharmacokinetics and pharmacodynamics of antimicrobials: a report of patients with neutropenia and fever. *Rev Chilena Infectol* 2011, **28**:537–545.
2. Theuretzbacher U: Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer. *Clin Infect Dis* 2012, **54**:1785–1792.
 3. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. *Clin Infect Dis* 2011, **52**:e56–e93.
 4. Drusano GL, DeJongh C, Newman K, Joshi J, Wharton R, Moody MR: Moxalactam and Piperacillin: a study of in vitro characteristics and pharmacokinetics in cancer patients. *Infection* 1985, **13**:20–26.
 5. Drusano GL, Forrest A, Plaisance KI, Wade JC: A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients. *Clin Pharmacol Ther* 1989, **45**:635–641.
 6. Levey AS, Coresh J, Bolton K, Culleton B, Schiro K, Alp T: Guidelines for chronic kidney disease: evaluation, classification and stratification. *Am J Kidney Dis* 2002, **39**(Suppl 1):S1–S266.
 7. Infante-Rivard C, Esnaola S, Villeneuve JP: Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. *Hepatology* 1987, **7**:660–664.
 8. Ritschel WA, Kearns JL: *Handbook of Basic Pharmacokinetics*. 4th edition. American Pharmacists Association: Washington; 1992.
 9. Mattoes HM, Capitano B, Kim MK, Xuan D, Quintiliani R, Nightingale CH: Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6h. *Chemother* 2002, **48**:59–63.
 10. Strayer AH, Gilbert DH, Pivarnik P, Medeiros AA, Zinner SH, Dudley MN: Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection. *Antimicrob Agents Chemother* 1994, **38**:2351–2356.
 11. Shea KM, Cheatham C, Matthew F, Wack M, Smith DW, Sowinski KM, Kays MB: Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered via prolonged infusion in hospitalised patients. *Internat J Antimicrob Agents* 2009, **34**:429–433.
 12. Auclair B, Ducharme MP: Piperacillin and tazobactam exhibit linear pharmacokinetics after multiple standard clinical doses. *Antimicrob Agents Chemother* 1999, **43**:1465–1468.
 13. Benet LZ, Kroetz DL, Sheiner LB: *Pharmacokinetics*, Goodman & Gilman's the pharmacological basis of therapeutics, Volume 1.1. 2nd edition. Philadelphia: McGraw Hill; 2011:3–29.
 14. Langgartner J, Lehn J, Glück T, Herzig H, Kees F: Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion. *Chemother* 2007, **53**:370–377.

doi:10.1186/2050-6511-14-59

Cite this article as: Álvarez et al.: Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy. *BMC Pharmacology and Toxicology* 2013 **14**:59.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

